{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(9)"],"submitter":["Martelli V"],"pubmed_abstract":["<h4>Background</h4>Circulating tumor DNA (ctDNA) variations predict tumor response to systemic treatment (so-called molecular response) earlier than radiological assessment. However, a standardized categorization of molecular response is an unmet clinical need. Liquid biopsy-RECIST (LB-RECIST), based on aggregate variant allele frequency (aggVAF; sum of all detected variant allele frequencies in a sample) variations, has been proposed to stratify molecular response. Metastatic colorectal cancer (mCRC) may be an attractive clinical scenario for LB-RECIST clinical implementation; however, specific data on clinical validity is still lacking.<h4>Patients and methods</h4>The prospective PLATFORM-B study enrolled 130 mCRC patients who received standard frontline treatment and underwent serial ct"],"journal":["ESMO open"],"pagination":["105760"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12446507"],"repository":["biostudies-literature"],"pubmed_title":["Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study."],"pmcid":["PMC12446507"],"pubmed_authors":["Elez E","Ferreiro R","Manzano JL","Alonso V","Martelli V","Pineda E","Bellosillo B","Montagut C","Gibert J","Gomez-Espana MA","Toledo R","Salazar R","Losa F","Aranda E","Paez D","Guix M","Cano MT","Garcia-Alfonso P","Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","Tabernero J","Sibilio A","Linares J","Fernandez-Rodriguez MC","Santos C","Rivera F","Vidal J","Duran G","Garcia-Carbonero R","Sastre J"],"additional_accession":[]},"is_claimable":false,"name":"Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study.","description":"<h4>Background</h4>Circulating tumor DNA (ctDNA) variations predict tumor response to systemic treatment (so-called molecular response) earlier than radiological assessment. However, a standardized categorization of molecular response is an unmet clinical need. Liquid biopsy-RECIST (LB-RECIST), based on aggregate variant allele frequency (aggVAF; sum of all detected variant allele frequencies in a sample) variations, has been proposed to stratify molecular response. Metastatic colorectal cancer (mCRC) may be an attractive clinical scenario for LB-RECIST clinical implementation; however, specific data on clinical validity is still lacking.<h4>Patients and methods</h4>The prospective PLATFORM-B study enrolled 130 mCRC patients who received standard frontline treatment and underwent serial ct","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T14:29:06.795Z","creation":"2026-04-28T03:11:41.127Z"},"accession":"S-EPMC12446507","cross_references":{"pubmed":["40907207"],"doi":["10.1016/j.esmoop.2025.105760"]}}